UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 41

Sortiert nach

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2 -positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

The lancet oncology, 2013-12, Vol.14 (13), p.1317-1325

2013

Link zum Volltext

Verfügbarkeit prüfen

Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network

Journal of clinical oncology, 2013-01, Vol.31 (2), p.210-216

2013

Link zum Volltext

Verfügbarkeit prüfen

Hispanic breast cancer patients’ symptom experience and patient-physician communication during chemotherapy

Supportive care in cancer, 2019-02, Vol.27 (2), p.697-704

2019

Link zum Volltext

Verfügbarkeit prüfen

The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial

Cancer prevention research (Philadelphia, Pa.), 2021-07, Vol.14 (7), p.753-762

2021

Link zum Volltext

Verfügbarkeit prüfen

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial

JAMA oncology, 2019-01, Vol.5 (1), p.45

2019

Link zum Volltext

Verfügbarkeit prüfen

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

Journal of clinical oncology, 2020-03, Vol.38 (7), p.674-685

2020

Link zum Volltext

Verfügbarkeit prüfen

Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data

American journal of hematology/oncology, 2016-07, Vol.12 (7), p.4-9

2016

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

Annals of oncology, 2015-07, Vol.26 (7), p.1280-1291

2015

Link zum Volltext

Verfügbarkeit prüfen

Local-regional recurrence following neoadjuvant endocrine therapy: Data from ACOSOG Z1031 (Alliance), a randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–positive clinical stage 2 to 3 breast cancer

Annals of surgical oncology, 2023-01, Vol.30 (4), p.2111-2118

2023

Link zum Volltext

Verfügbarkeit prüfen

Whole―genome analysis informs breast cancer response to aromatase inhibition

Nature (London), 2012-06, Vol.486 (7403), p.353-360

2012

Link zum Volltext

Verfügbarkeit prüfen

Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA‐negative Hispanics with breast cancer

Cancer, 2019-08, Vol.125 (16), p.2829-2836

2019

Link zum Volltext

Verfügbarkeit prüfen

American College of Surgeons Oncology Group and the community surgeon

Surgical oncology clinics of North America, 2011-07, Vol.20 (3), p.439

2011

Link zum Volltext

Verfügbarkeit prüfen

Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer

Annals of surgical oncology, 2023-04, Vol.30 (4), p.2111-2118

2023

Link zum Volltext

Verfügbarkeit prüfen

A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance)

Cancer, 2021-01, Vol.127 (2), p.291-299

2021

Link zum Volltext

Verfügbarkeit prüfen

ASO Visual Abstract: Local-Regional Recurrence Following Neoadjuvant Endocrine Therapy – Data from ACOSOG Z1031 (Alliance), a Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor–Positive Clinical Stage 2–3 Breast Cancer

Annals of surgical oncology, 2023-04, Vol.30 (4), p.2119-2120

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract PD9-03: Pam50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the alternate trial (Alliance A011106)

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD9-03-PD9-03

2022

Link zum Volltext

Verfügbarkeit prüfen

Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles

Annals of surgical oncology, 2020-07, Vol.27 (7), p.2269-2275

2020

Link zum Volltext

Verfügbarkeit prüfen

ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.504-504

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(39)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(41)

Sprache

Englisch
(41)
Japanisch
(4)

Erscheinungsjahr

n.n

Thema

Humans
(21)
Science & Technology
(20)
Female
(19)
Life Sciences & Biomedicine
(19)
Oncology
(17)
Breast Cancer
(10)
Breast Neoplasms - Pathology
(10)
Middle Aged
(10)
Breast Neoplasms - Drug Therapy
(9)
Aged
(8)
Adult
(7)
Breast Neoplasms - Surgery
(7)
Surgery
(7)
Neoadjuvant Therapy
(5)
Anastrozole
(4)
Androstadienes - Therapeutic Use
(4)
Aromatase Inhibitors - Therapeutic Use
(4)
Breast Neoplasms - Chemistry
(4)
Chemotherapy
(4)
Medicine
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Phase II Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women With Estrogen Receptor–Rich Stage 2 to 3 Breast Cancer: Clinical and Biomarker Outcomes and Predictive Value of the Baseline PAM50-Based Intrinsic Subtype—ACOSOG Z1031

Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2 -positive breast cancer (Z1041): a randomised, controlled, phase 3 trial

Prevalence and Type of BRCA Mutations in Hispanics Undergoing Genetic Cancer Risk Assessment in the Southwestern United States: A Report From the Clinical Cancer Genetics Community Research Network

Hispanic breast cancer patients’ symptom experience and patient-physician communication during chemotherapy

The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial

Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

Effect of Vitamin D Supplementation on Breast Cancer Biomarkers: CALGB 70806 (Alliance) Study Design and Baseline Data

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group

Local-regional recurrence following neoadjuvant endocrine therapy: Data from ACOSOG Z1031 (Alliance), a randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–positive clinical stage 2 to 3 breast cancer

Whole―genome analysis informs breast cancer response to aromatase inhibition

Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA‐negative Hispanics with breast cancer

American College of Surgeons Oncology Group and the community surgeon

Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer

Health‐related quality of life outcomes for the LEAP study—CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients

A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance)

Abstract PD2-10: Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106)

Abstract GS4-05: Neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (Alliance A011106)

Clinical Trials for the Surgical Oncologist: Opportunities and Hurdles

ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106

Suchergebnisse filtern